Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Levetiracetam].

J Salas-Puig1, S Calleja

  • 1Servicio de Neurología II. Hospital Central de Asturias, Oviedo. jsalasp@meditex.es

Neurologia (Barcelona, Spain)
|December 18, 2001
PubMed
Summary
This summary is machine-generated.

Levetiracetam, a novel antiepileptic drug, demonstrates favorable pharmacokinetics and is effective for partial-onset seizures. It is well-tolerated with minimal drug interactions, offering a promising treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment outcomes in sinonasal aspergillosis in dogs in the United Kingdom: 436 cases (2011-2021).

The Journal of small animal practice·2025
Same author

Diagnostic findings in sinonasal aspergillosis in dogs in the United Kingdom: 475 cases (2011-2021).

The Journal of small animal practice·2024
Same author

Management of cerebral venous thrombosis in Spain: MOTIVATE descriptive study.

Neurologia·2023
Same author

Overnight switch from levetiracetam to brivaracetam. Safety and tolerability.

Epilepsy & behavior reports·2021
Same author

Management of cerebral venous thrombosis in Spain: MOTIVATE descriptive study.

Neurologia·2021
Same author

[Quality of life in adult patients with idiopathic generalised epilepsy. The EPILAK study].

Revista de neurologia·2021
Same journal

[Amyotrophic neuralgia secondary to Vaxzevria (AstraZeneca) COVID-19 vaccine].

Neurologia (Barcelona, Spain)·2024
Same journal

[SARS-CoV-2 infection: Possible underdiagnosis of cerebral venous sinus thrombosis].

Neurologia (Barcelona, Spain)·2024
Same journal

[Bell's palsy following COVID-19 vaccination: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Parsonage-Turner syndrome post-infection by SARS-CoV-2: A case report].

Neurologia (Barcelona, Spain)·2024
Same journal

[Acute transverse myelitis following SARS-CoV-2 infection].

Neurologia (Barcelona, Spain)·2024
Same journal

[Neurological complications in critical patients with COVID-19].

Neurologia (Barcelona, Spain)·2024
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Therapeutics

Background:

  • Levetiracetam is a novel antiepileptic drug (AED) with a unique chemical structure.
  • Its pharmacological properties differ from piracetam, despite structural similarities.

Purpose of the Study:

  • To review the pharmacokinetic profile, efficacy, and tolerability of levetiracetam.
  • To assess its potential in treating various seizure types and patient populations.

Main Methods:

  • Review of preclinical data and pivotal clinical trials.
  • Analysis of pharmacokinetic parameters including bioavailability, kinetics, protein binding, and metabolism.
  • Evaluation of adverse events and drug interactions.

Main Results:

Related Experiment Videos

  • Levetiracetam exhibits ideal pharmacokinetic properties for an AED: good bioavailability, linear kinetics, rapid steady-state achievement, minimal protein binding, and low metabolism.
  • Four pivotal trials confirmed its efficacy as add-on therapy for adult partial-onset seizures.
  • The drug is well-tolerated, with an adverse event profile similar to placebo, and no significant interactions with common medications.

Conclusions:

  • Levetiracetam presents an excellent pharmacokinetic profile and proven efficacy for partial-onset seizures in adults.
  • Its favorable tolerability and lack of drug interactions enhance its therapeutic potential.
  • Further research is needed on its efficacy in monotherapy and in pediatric populations, as well as for generalized seizures.